Product Description
CR1447 (4-hydroxytestosterone, 4-OHT) binds to the androgen receptor and has antiproliferative activity in both ER-positive and ER-negative/AR-positive breast cancer cells in preclinical studies. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28814476/)
Mechanisms of Action: AR Agonist
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Swiss Group for Clinical Cancer Research
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Breast Cancer|Adenocarcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SAKK 21/12 | P2 |
Terminated |
Breast Cancer|Adenocarcinoma |
2018-08-02 |